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Abstract
The objective of this study was to investigate a possible mechanism of action of metronomic
chlorambucil on glioma by studying the in vitro cytotoxicity and anti-angiogenic effects on gli-
oma and endothelial cells, respectively. The in vitro LD50 and IC50 of chlorambucil were
determined using human SF767 and U87-MG glioma cell lines, human microvascular endo-
thelial cells (HMVECs) and human endothelial colony forming cells (ECFCs). Results were
analyzed in the context of chlorambucil concentrations measured in the plasma of tumor-
bearing dogs receiving 4 mg m-2 metronomic chlorambucil. The LD50 and IC50 of chlorambu-
cil were 270 μM and 114 μM for SF767, and 390 μM and 96 μM for U87-MG, respectively.
The IC50 of chlorambucil was 0.53 μM and 145 μM for the HMVECs and ECFCs, respec-
tively. In pharmacokinetic studies, the mean plasma Cmax of chlorambucil was 0.06 μM.
Results suggest that metronomic chlorambucil in dogs does not achieve plasma concentra-
tions high enough to cause direct cytotoxic or growth inhibitory effects on either glioma or
endothelial cells.
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Introduction
Gliomas are common primary brain tumors in both human and veterinary medicine. A diag-
nosis of a high-grade glioma carries a poor prognosis due to frequent disease recurrence [1–2].
Treatment strategies for gliomas have evolved over the last few decades; however, for patients
with high-grade gliomas, there has only been modest changes in overall survival rates, even
with improvements in cytoreductive surgery, radiation therapy techniques, and the addition of
newer chemotherapy agents and targeted therapies [2–4].
One of the intriguing new approaches to cancer treatment is the use of relatively low, fre-
quent dosing of chemotherapy agents, in a “metronomic” fashion to target tumor angiogenesis
[5–8]. This contrasts to conventional chemotherapeutic protocols that utilize a maximum tol-
erated dose of drug given with prolonged breaks in between dosing to directly have an effect
on tumor cells. The mechanism by which metronomic chemotherapy affects tumor angiogene-
sis and potentially other processes has yet to be fully elucidated. The mechanism is likely multi-
factorial, including targeting tumor angiogenesis through a direct effect on activated vascular
endothelial cells and circulating endothelial progenitor cells, but it may also be mediated by
prostaglandins, thrombospondin 1, growth factors, as well as other potential mediators of vas-
culogenesis [5,7–9].
An appealing aspect of metronomic chemotherapy is a lower risk of toxicity compared to
standard chemotherapy [10–12]. Additionally, drugs or protocols that target tumor angiogene-
sis, such as metronomic therapy, should have activity against, in theory, all tumor types. In
addition, previous reports have demonstrated efficacy of metronomic chemotherapy in tumors
that have become resistant to conventional chemotherapy protocols, even when using the
same chemotherapy agents that had shown resistance when administered in conventional dos-
ing protocols [10,13–14].
Metronomic chemotherapy has been shown to have potential benefits in human patients
with glioma [11–12,15–16]. Patient selection likely affects these results, as this therapy is more
commonly utilized in patients with high grade gliomas. In these cases, disease progression
occurs after a combination of surgical resection, radiation therapy, and standard chemother-
apy dosing with temozolomide, which are the common therapies utilized depending on tumor
grade [1,3,17–18]. Conventional chemotherapy options for glioma are limited due to the avail-
ability of drugs that penetrate the blood brain barrier (BBB). However, since the blood vessels
are a component of the blood brain barrier, targeting glioma vasculogenesis may eliminate the
necessity to select for a drug that crosses the BBB. Targeting tumor vasculogenesis in glioma,
especially high-grade glioma, is a reasonable objective as these are commonly vascular tumors
[19–20].
Chlorambucil is an alkylating agent that has been reported to inhibit neovascularization via
its effect on circulating endothelial progenitor cells, induction of endothelial cell apoptosis,
and inhibition of endothelial cell migration [21]. Chlorambucil has been used in the treatment
of several tumor types in canine patients, with reported activity against chronic lymphocytic
leukemia, lymphoma, and myeloma [22–24]. Metronomic chlorambucil has been reported to
be effective with minimal toxicity in dogs with multiple types of naturally occurring cancers, at
a dose of 4 mg m-2 per day [10], although prolonged use, especially beyond a year, or higher
dosing at 8 mg m-2, has been associated with chronic myelosuppression in some dogs [25].
The purpose of this study was to investigate putative mechanisms of action of metronomic
chemotherapy with chlorambucil against canine glioma cell lines, for use in advancing our
understanding of the potential use of metronomic chlorambucil in veterinary neurooncology,
and potential application to human neurooncology. There were three specific objectives. The
first objective was to determine the in vitro median lethal dose (LD50) and the concentration
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that inhibited proliferation by 50% (IC50) of chlorambucil using two human glioma cell lines,
SF767 and U87-MG. This establishes the concentrations of chlorambucil that would be neces-
sary to directly inhibit proliferation of these cells. The second objective was to determine the
effects of chlorambucil in inhibiting proliferation and tube formation in two human endothe-
lial cell lines, human microvascular endothelial cells (HMVECs) and human progenitor
derived endothelial colony forming cells (ECFCs). The final objective was to perform in vivo
pharmacokinetic analyses of single-dose chlorambucil in dogs, to determine if the peak chlor-
ambucil concentrations achieved would approximate the anti-proliferative and anti-angio-
genic concentrations found in vitro. The hypothesis, based on previously reported clinical
response, was that the IC50 and LD50 of endothelial cells would be lower than that for the gli-
oma cells, and would approximate the peak concentrations achieved in vivo.
Materials and methods
All animal work was approved by the Purdue University Institutional Animal Care and Use
Committee (Protocol 11–029, approved June 2, 2011).
Cell lines and culture conditions
SF767 (temozolomide resistant) and U87-MG (temozolomide sensitive) human glioma cell
lines (In Vivo Therapeutics Core of the Indiana University Melvin and Bren Simon Cancer
Center, Indianapolis, IN, USA) were grown as monolayers in 75 cm2 tissue culture flasks in
Iscove’s Modified Dulbecco’s Medium (IMDM), supplemented with 10% fetal bovine serum
(FBS), 1% glutamine, 100 IU/mL penicillin and 100 μg/mL streptomycin mixture. Cell cultures
were maintained at 370 C in a humidified 5% CO2 atmosphere, and sub-cultured three times
each week. All assays using glioma cell lines were done independently in triplicate, using cell
cultures at low passages. HMVECs and umbilical cord blood derived ECFCs (Angio BioCore
[ABC]), Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA)
were seeded on 75 cm2 tissue culture flasks pre-coated with type 1 rat tail collagen in complete
Endothelial Cell Growth Medium (EGM-2) for passage.
SF767 and U87-MG cell proliferation
Sulforhodamine B (SRB) assay (Sigma, St Louis, MO, USA) was performed as previously
described [26], to determine the concentration of chlorambucil (Leukeran1, GlaxoSmithK-
line, Research Triangle Park, NC, USA) resulting in 50% growth inhibition (IC50). Briefly, the
cells were detached using a trypsin-EDTA mixture and were plated using 5x104 cells per well
in a flat-bottom 96 well plate. The cells were incubated for 24 hours to allow for adherence
before treatment. Chlorambucil in 1% DMSO was applied in the following concentrations:
1000, 500, 100, 10, 1, 0.1 and 0.01 μM (8 wells per condition). The cells were incubated follow-
ing treatment for 48 hours, at which time the cells were fixed. Cold trichloroacetic acid (10%
final concentration) was gently added to each well, incubated at 40 C for 1 hour, washed 5
times with distilled water, and air-dried. The fixed cellular proteins were stained using 50 μL
0.4% SRB in 1% acetic acid, and incubated at room temperature for 30 minutes. The wells
were washed five times using a 1% acetic acid solution and then air-dried. Bound SRB was
then solubilized using 200 μL of 10 mM Tris-base solution, and the absorbance was evaluated
in a 96 well EMax Endpoint ELISA Microplate Reader (Molecular Devices LLC, Sunnyvale,
CA, USA) at 490 nm. Using three independent replications, the optical densities of wells for
each condition (different drug concentrations or vehicle control) were averaged, and data
expressed as percent growth of control. The mean and standard deviation of the replicate
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analyses were graphed using Excel1 (Microsoft, Corp, Redmond, WA, USA), which was then
used to determine the IC50.
SF767 and U87-MG cell viability
Cellular apoptosis and necrosis were evaluated with the Annexin V-FITC/7-AAD kit staining
protocol (BD Biosciences, Sparks, MD, USA), followed by fluorescence-activated cell sorting
(FACS) analysis. The cells were detached using a trypsin-EDTA mixture and plated using
1x105 cells per well in a 12 well plate. The cells were allowed 24 hours for adherence before
treatment. Chlorambucil in 1% DMSO was added at each of the following concentrations: 500,
100, 10, 1, 0.1, and 0.01 μM. Cellular viability was evaluated at 4, 24, and 48 hours after expo-
sure to chlorambucil. The supernatant, along with the cells after the addition of trypsin-EDTA
mixture were collected from each well and centrifuged at 300 rpm for 5 minutes at 40 C. The
pellet was washed twice with 1 mL Dulbecco’s Phosphate Buffered Saline (DPBS) each time.
The pellet was then re-suspended in 100 μL 1X binding buffer, and then 5 μL of Annexin
V-FITC and 5 μL of 7-AAD solutions were added. The suspensions were incubated for 15 min-
utes at room temperature in the dark, after which 400 μL of 1X binding buffer was added. A
total of 5000 events from each suspension were collected using FACS analysis with a BD FACS
Canto II (Becton Dickinson and Company, Franklin Lakes, NJ, USA). The output was then
analyzed using FlowJo (Version X.0.6, Tree Star, Inc, Ashland, OR, USA) to determine the per-
centage of healthy cells (unstained), early apoptotic cells (Annexin V-FITC positive), and late
apoptotic cells (Annexin V-FITC and 7-AAD positive). Initial gating was based on Forward
Scatter and Side Scatter characteristics to eliminate debris. Samples of the gating procedures
for SF767 and U87-MG after 48 hours of drug exposure are provided (Fig 1). The percentages
of cells in early and late apoptosis were added to determine the total percentage undergoing
cell death. The mean and standard deviation of the percent cytotoxicity of the replicate analy-
ses were graphed on Excel1 using a logarithmic scale at 4, 24, and 48 hours. Using these plots,
the drug concentration resulting in death in 50% of the cells (LD50) after 48 hours after drug
exposure was determined.
HMVEC and ECFC thymidine incorporation assay
Thymidine incorporation proliferation assays were conducted as previously described with
slight modifications [27]. Cultured HMVECs and ECFCs were seeded onto a 96 well plate in
EGM-2 at a density of 3000 cells per well. The cells were starved for 24 hours in Endothelial
Basal Medium-2 (EBM-2) containing 2% FBS and then stimulated using Chlorambucil in 1%
DMSO at the following concentrations: 1000, 500, 100, 10, 1, 0.1 and 0.01 μM for 16 hours.
1μL of tritiated thymidine was then added per well and incubated at 370 C for 7 hours. The
cells were then harvested and placed onto a Unifilter 96-well plate and read on a plate reader
for β emission (Perkin Elmer, PerkinElmer, Inc, Waltham, MA, USA). Assays were performed
in quadruplicate.
HMVEC and ECFC matrigel tube formation assay
Matrigel assays to assess tube formation were conducted as previously described with slight
modifications [28]. Briefly, early passage (i.e. 2–3) HMVECs and ECFCs were starved over-
night and then seeded onto a 96-well tissue culture plate coated with 45 μL of Matrigel (BD
Biosciences, Sparks, MD, USA) at a cell density of 7500 cells per well. Chlorambucil was tested
in 1% DMSO at the following concentrations: 1000, 500, 100, 10, 1, 0.1 and 0.01 μM. Cells
were observed every 2 hours by visual microscopy with an inverted microscope at 40X
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magnifications for tube formation. Wells were quantified at 8 hours post plating. Assays were
performed in triplicate.
Pharmacokinetic sampling
The dog studies were conducted following the guidelines and approval of the Purdue Animal
Care and Use Committee (Protocol 11–029, approved June 2, 2011), and informed consent
was obtained from all owners prior to participation. The participating dogs were client-owned
pet dogs who presented to the Purdue University Veterinary Teaching Hospital for treatment
of their naturally-occurring cancer. As this study aim was exclusively to acquire PK data,
tumor type was irrelevant, and dogs were eligible for enrollment for any tumor type (not spe-
cifically brain tumor), provided they were treatment naïve for chlorambucil and previously
scheduled to begin a metronomic chlorambucil treatment protocol. The 5 participating dogs
received oral chlorambucil at 4 mg m-2 per day as part of their cancer therapy. Plasma samples
were obtained at 0 (prior to administration of the first dose of chlorambucil), 5, 10, and 30
minutes, and then 1, 2, 4, and 8 hours after the first dose. The mean and range of the half-life
(t1/2), time to peak serum concentration (tmax), peak serum concentration (Cmax), area under
the curve (AUC), and clearance were determined.
Fig 1. FACS analysis plots. Representative examples of plots obtained using Annexin V and 7-AAD evaluated with FACS analysis, used to determine
gaiting (A and C) and evaluation of the control samples (B and D) for SF767 (A and B) and U87-MG (C and D) glioma cell lines. The percentage of early
apoptotic cells (lower right quadrant) and late apoptotic cells (upper right) were then used in assessment of cytotoxicity.
https://doi.org/10.1371/journal.pone.0203517.g001
Metronomic chlorambucil for glioma
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Quantification of plasma chlorambucil
Chlorambucil was quantified in dog plasma and urine by internal standardization, protein pre-
cipitation with acetone, and HPLC-MS/MS (Thermo TSQ Quantum Ultra, Thermo Scientific,
Waltham, MA, USA). Chlorambucil and melphalan, the internal standard, were separated on
a C18 4.6 X 100 mm column (Phenomenex Onyx Monolithic, Torrance, CA, USA) using a lin-
ear gradient mixing the mobile phases. Mobile phase A was acetonitrile: 0.1% formic acid
(20:80, v/v) and mobile phase B was acetonitrile: 0.1% formic acid (80:20, v/v). The linear gra-
dient started with 100% mobile phase A at the time of injection and was 100% mobile phase B
at 6 minutes. The mass spectrometer utilized an electrospray ionization probe and was run in
positive mode. The selected reaction monitoring (SRM) Q1/Q3 (m/z) transition for chloram-
bucil and melphalan was 305/169 and 306/247, respectively. The lower limit of quantification
was 1 ng/mL using 100 μL plasma.
Pharmacokinetic analysis
The maximum plasma concentration (Cmax), was obtained from the data. Pharmacokinetic
parameters for chlorambucil were estimated using non-compartmental methods with add-ins
on Excel1. The half-life (t1/2), was estimated by 0.693/kel, where kel is the elimination rate
constant. The average chlorambucil concentrations (n = 5 dogs) were used to model the phar-
macokinetics using PK Solver in Excel1. The data best fit a one compartmental model after
an extravascular dosage (4 mg m-2). Estimates, including the absorption rate constant, ka, t½,
the time of maximum concentration, tmax, and kel, from this model were used to forecast Cmax,
assuming linear conditions after single dosage administration.
Results
SF767 and U87-MG cell proliferation assay
The determined IC50 of chlorambucil was 114 μM for SF767 cells and 96 μM for U87-MG cells
(Fig 2).
SF767 and U8-MG7 cell viability assay
There was minimal evidence of cytotoxicity at 4 hours, which subsequently increased over 24
and 48 hours (Fig 3). At 48 hours, the LD50 was 270 μM for the SF767 cells and 390 μM for the
U87-MG cells.
HMVEC and ECFC proliferation and tube formation assays
The IC50 for inhibition of tube formation using the Matrigel assay was 0.53 μM and 145 μM
for the HMVECs and ECFCs, respectively (Fig 4). When comparing the tube formation as a
percentage of control, tube formation was 56% and 84% in the 1% DMSO well compared to
the cells only control. Tube formation in the remaining concentrations reached 50% suppres-
sion at 1 μM and 1000 μM for the HMVECs and ECFCs, respectively. For the thymidine incor-
poration proliferation assays, the LD50 of both the HMVECs and ECFCs was 1000 μM.
Chlorambucil pharmacokinetic profile in tumor-bearing dogs
A single chlorambucil dose of approximately 4 mg m-2 per day (actual dose range 3.80–4.76
mg m-2) in dogs yielded a mean t1/2 of 1.7 hours (range 0.9–3.6 hours) with a mean Cmax of
20.6 ng/mL (range 4.5–31.3 ng/mL) (Fig 5). The mean Cmax of 20.6 ng/mL is equivalent to a
concentration of 0.06 μM (range of all dogs 0.01–0.09 μM). The results of the pharmacokinetic
Metronomic chlorambucil for glioma
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analyses are depicted in Table 1. Modeling was performed to calculate the oral metronomic
dose required to reach a Cmax that matched the results of the in vitro studies. The current 4 mg
m-2 dose administered resulted in average plasma Cmax of 0.06 μM. In order to reach a Cmax of
0.1, 20, and 100 μM, an oral dose of 86, 1730 and 8500 mg m-2, respectively, would be required
based on the modeling estimates.
Discussion
As expected, the concentration of chlorambucil necessary to inhibit human endothelial cell
proliferation was generally lower than the concentration necessary to inhibit human glioma
cell proliferation and cause direct cytotoxicity. The HMVECs and ECFCs differed in their
response to chlorambucil, which may be due to differences in maturity of endothelial cell
types. HMVECs are mature endothelial cells collected from the microvasculature of the lung
whereas the cord blood derived ECFCs contain high numbers of immature progenitor cells
that contribute to de novo vessel formation [27]. Furthermore, it has been previously reported
that ECFCs have a higher proliferative capacity compared to endothelial cells of other, more
mature, origins [29]. Surprisingly, the concentrations of chlorambucil required to inhibit the
proliferation and tube forming activity of either type of endothelial cells in vitro was much
higher than chlorambucil concentrations achieved in vivo in tumor-bearing dogs. The previ-
ously reported clinical effect using metronomic chlorambucil in dogs, in which the reported
dose resulted in a remission rate of 4 of 36 (11%) dogs, and stabilized the disease in 17 of 36
(47%) dogs, does not correlate with the disparity between plasma concentration and the con-
centrations necessary to inhibit human endothelial cell proliferation [10]. Based on pharmaco-
kinetic modeling, the oral chlorambucil dosages necessary to attain a Cmax appropriate for
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Fig 2. SF767 and U87-MG growth inhibition. Calculated mean percent growth inhibition of increasing
concentrations of chlorambucil (0.01 to 1000 μM) against in vitro SF767 (gray dotted line) and U87-MG (black solid
line) glioma cell lines as determined using the Sulforhodamine B assay. Data are expressed in the figure by the % of
growth retained under each condition, compared to the control. The IC50 was then determined to be 114 μM and
96 μM for the SF767 and U87-MG glioma cell lines, respectively.
https://doi.org/10.1371/journal.pone.0203517.g002
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directly affecting endothelial cells in angiogenesis would be> 8500 mg m-2, which is not bio-
logically feasible in the dog. This would suggest that chlorambucil acts through mechanisms
other than those tested in vitro. These could include cell-cell interactions that enhance either
anti-angiogenic or cytotoxic effects that were not elucidated in pure cell line cultures, such as
paracrine effects, or co-factors from circulating tumor cells. There has also been consideration
recently that metronomic chemotherapy may elicit a pro-immunogenic effect through prolif-
eration of specific T-cell responses and NK cells, which is specific to the low drug dosages used
in metronomic chemotherapy, and the opposite effect of the leukocyte suppression elicited by
MTD regimes [30].
It is acknowledged that the in vitro assays in this study only assesses direct effects on endo-
thelial cell proliferation and tube formation, and that other proposed anti-angiogenic mecha-
nisms of metronomic chlorambucil would not be detected. This provides support for other
proposed mechanisms for metronomic chemotherapy on angiogenesis, and other processes
playing a larger role in the beneficial effects seen clinically with metronomic chlorambucil
Fig 3. SF767 and U87-MG cytotoxicity. Average percentage survival of cells with increasing concentrations of
chlorambucil (0.01 to 500 μM) against in vitro SF767 (gray dotted lines) and U87-MG (black solid lines) after 4 hours
(A), 24 hours (B), and 48 hours (C) of exposure using Annexin V and 7-AAD and FACS analysis. Using the sum of the
percentage of early apoptotic cells and late apoptotic cells as determined using FACS analysis, the LD50 after 48 hours
was 270 μM and 390 μM for SF767 and U87-MG glioma cell lines, respectively. Note that where the % survival relative
to control is greater than 100%, this is explained by insignificant cytotoxicity and natural variation of non-drug
dependent cell death at early time points and low drug dilutions, in which the fraction of surviving cells in the
experimental wells at lower concentrations and earlier time points was greater than that in the control wells, resulting
in an initial survival greater than 100%. As incubation time and drug concentration increase, cell death becomes
greater than the control and the data are more informative.
https://doi.org/10.1371/journal.pone.0203517.g003
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Fig 4. HMVEC and ECFC proliferation. In vitro determination of the mean percent tube formation of HMVECs (black
solid line) and ECFCs (gray dotted line) against increasing concentrations of chlorambucil (0.01 to 1000 μM) using the
Matrigel tube formation assay. Values are compared to control wells to provide a %. The concentration leading to a mean
percent growth inhibition was 0.53 μM and 145 μM for the HMVECs and ECFCs, respectively.
https://doi.org/10.1371/journal.pone.0203517.g004
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[10,14], though a clear mechanism of action of metronomic chlorambucil has not been estab-
lished with the results of the current study. Although gaps in the understanding of metronomic
chlorambucil for CNS tumors exist, a pilot study may further elucidate the mechanism of
action and determine preliminary efficacy. Tumor biopsies or surgical resection could be
obtained at a specific time point after administration of chlorambucil, in order to determine
tissue drug concentration. This would help elucidate whether tissue concentrations were sup-
portive of direct cytotoxic effect, or not, and could be matched with the in vitro data presented
here, along with clinical outcome data. This information also may inform whether additional
in vitro co-culture studies may further elucidate the mechanism of action. Further studies
could also include effects on other mediators of vasculogenesis, endothelial progenitor cells,
thrombospondin-1, as well as effects on regulatory T cells [8–9,31].
Another point that must be considered is whether canine and human endothelial cells
could respond differently to chlorambucil. There could be species differences regarding the
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Fig 5. Plasma concentration of chlorambucil. Log transformation of pharmacokinetic data for 5 dogs receiving 4 mg m-2
per day.
https://doi.org/10.1371/journal.pone.0203517.g005
Table 1. Pharmacokinetic data for 5 dogs receiving chlorambucil at 4 mg m-2 per day.
Dose
(mg m-2)
Cmax (ng/mL) Tmax (hours) t1/2 (hours)
Dog 1 4.76 31.32 0.50 1.57
Dog 2 3.80 4.50 0.17 3.63
Dog 3 4.17 17.00 1.00 1.46
Dog 4 4.39 28.20 1.00 0.86
Dog 5 4.25 21.50 1.00 0.96
Mean (SD) 4.27
(0.35)
20.50 (10.55) 0.73 (0.38) 1.70 (1.12)
https://doi.org/10.1371/journal.pone.0203517.t001
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sensitivity of endothelial cells against chlorambucil, as well as differences in sensitivity of endo-
thelial cells within the tumors compared to that of healthy tissues. Dog endothelial cell cultures
were not available at the time of our experiments, thus human endothelial cell cultures were
used in this study. However, in a mouse study, anti-angiogenic effects were only observed with
400 μM chlorambucil, while plasma concentrations ranged from 0.01 to 0.09 μM [21]. The
concentration of chlorambucil causing inhibition of vasculogenesis in the mouse embryonic
experiment was similar to the concentrations that inhibited angiogenesis using human endo-
thelial cells in our current study.
When humans have received doses of chlorambucil at or approaching the maximum toler-
ated dose (MTD), the peak plasma concentrations (3.6 μM) approach a concentration that
would inhibit proliferation in HMVECs [32]. It is interesting that due to relatively high bio-
availability of chlorambucil in humans (70%) that the MTD in humans (6 mg m-2) is only
slightly higher than the metronomic chemotherapy dosing in dogs, but achieves more than a
tenfold higher peak plasma concentration [33,34]. Although it is intriguing to consider that
MTD chlorambucil may have anti-angiogenic effects, the goal is to determine effective metro-
nomic dosing that will have less risk of toxicity than MTD dosing.
Metronomic chemotherapy and other targeted therapies for tumor vasculogenesis are cur-
rently being explored for human patients with high-grade glioma, especially upon recurrence
of disease. There are a limited number of reports evaluating the effects of metronomic chemo-
therapy, most commonly temozolamide, on patients with glioma. These studies utilized vari-
ous metronomic chemotherapy drug protocols in patients with recurrent malignant gliomas,
with some demonstrating improvement in progression free survival and some showing no
benefit [11–12,15–16,35]. Patient selection likely contributes to the variability in these results.
Most of these reports include patients that have disease recurrence following surgical resection,
radiation therapy, and chemotherapy prior to the use of metronomic therapy, thus suggesting
a more aggressive disease. The differences in response to treatment could also be attributed to
the metronomic chemotherapy regimen that is utilized.
More research is needed in order to elucidate the actual benefit of metronomic chemother-
apy for brain tumors, and which drug, or drug combination, is most beneficial. Work in dogs
could prove extremely valuable in this research. Canine glioma is an accepted model for
human glioma, and more closely mimics the human condition than xenograft models [36–38].
High grade gliomas in both humans and dogs are spontaneous tumors, heterogenous, infiltra-
tive, and have many similar histopathologic findings and genetic alterations [36–38]. Although
comprehensive comparisons of genetic and immunological characteristics are not yet avail-
able, similarities of significance that have been identified include chromosome copy number
aberrations (gains or losses among several chromosomes) [38, 39], neovascularization [40],
and endothelial/microvascular proliferation [40], while key differences include mutagenesis of
IDH1 and IDH2 [41]. Of importance to further study in this model is the tumor tissue penetra-
tion of chlorambucil. It is known that in normal rat brain the brain tissue:plasma ratio of
chlorambucil is 0.021, indicating poor penetration of the BBB [42]; however, this may not rep-
resent the concentration in tumor tissue.
Metronomic chemotherapy with chlorambucil has been demonstrated to be efficacious and
well tolerated when used to treat multiple types of cancer in dogs [10,14,25]. In these studies,
the majority of side effects were classified as grade 1–2 gastrointestinal toxicity, with some
grade 1–2 thrombocytopenia and lethargy, according to the Veterinary Co-operative Oncology
Group [43,25]. More severe adverse events, such as persistent thrombocytopenia or severe
lethargy, were rarely reported [25].
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